Lilly Drug Reduces Blindness in Diabetic Patients
Posted on: Tuesday, 14 November 2006, 06:00 CST
Eli Lilly has said results from a three-year phase III clinical trial suggested its experimental drug Arxxant reduced the risk of vision loss by 40% in patients with diabetic retinopathy.
Diabetic retinopathy (DR) occurs when diabetes damages the small blood vessels in the retina, a part of the eye that is needed for vision. This damage can lead to vision loss and possible blindness.
This phase III clinical trial examined whether Arxxant could reduce the risk of long-term, or sustained moderate vision loss caused by non-proliferative diabetic retinopathy. Vision loss occurred in only 5.5% of patients treated with Arxxant compared to 9.1% of patients treated with placebo, equaling a 40% relative risk reduction over three years.
Patient discontinuations due to adverse events were not statistically different between treatment groups. There were 36 patient deaths none of which were considered by the investigator or sponsor to be related to study drug.
Eli Lilly is currently challenging a decision by the FDA that requested an additional phase III study of Arxxant before it could be approved.
Source: Datamonitor
Related Articles
- Clues To Visual Variant Alzheimer's; Myopia And Diabetic Retinopathy Risk
- Glycemic Control Appears to Reduce Type 1 Diabetics' Retinopathy Risk
- Previously Unrecognized Harm of Intensified Glucose Lowering Reported in High Risk Patients With Type 2 Diabetes
- American Academy Of Ophthalmology Urges Diabetics To Get Their Eyes Screened To Avoid Complications And Vision Loss Of Diabetic Retinopathy
- Lilly: Arxxant Cuts Sight Loss in Diabetes
- Lilly Drug Cuts Vision Loss in Diabetic Eye Disease
- Inoveon Completes 40,000th iScan(TM); Company Estimates It Has Helped Detect Vision-Threatening Disease in More Than 3,200 Patients With Diabetes
- Molecule Linked to Vision Loss in Diabetics
- Diabetic Retinopathy Occurs in Pre-Diabetes Patients
- Associations of Mortality and Diabetes Complications in Patients With Type 1 and Type 2 Diabetes: Early Treatment Diabetic Retinopathy Study Report No. 27
 |
 |
User Comments (0)
RSS Feeds